[PDF][PDF] Integrative clinical genomics of advanced prostate cancer

…, Y Chen, DE Rathkopf, MJ Morris, SB Solomon… - Cell, 2015 - cell.com
Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …

[PDF][PDF] Organoid cultures derived from patients with advanced prostate cancer

…, SF Slovin, SB Solomon, JA Eastham, P Chi, B Carver… - Cell, 2014 - cell.com
The lack of in vitro prostate cancer models that recapitulate the diversity of human prostate
cancer has hampered progress in understanding disease pathogenesis and therapy response…

Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update

…, SC Rose, R Salem, CT Sofocleous, SB Solomon… - Radiology, 2014 - pubs.rsna.org
Image-guided tumor ablation has become a well-established hallmark of local cancer
therapy. The breadth of options available in this growing field increases the need for …

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

…, GR Oxnard, K Nafa, GJ Riely, SB Solomon… - Clinical cancer …, 2011 - AACR
Background: The epidermal growth factor receptor (EGFR) mutation T790M is reported in
approximately 50% of lung cancers with acquired resistance to EGFR inhibitors and is a …

A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti–PD-1 agent pembrolizumab

PS Adusumilli, MG Zauderer, I Rivière, SB Solomon… - Cancer discovery, 2021 - AACR
Regional delivery of mesothelin-targeted CAR T-cell therapy followed by pembrolizumab
administration is feasible, safe, and demonstrates evidence of antitumor efficacy in patients …

Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making

…, K Curtis, DM Hyman, JC Durack, SB Solomon… - JCO precision …, 2017 - ascopubs.org
Purpose A long natural history and a predominant osseous pattern of metastatic spread are
impediments to the adoption of precision medicine in patients with prostate cancer. To …

[HTML][HTML] Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with …

…, C Beattie, B Zhao, SB Solomon… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose Transarterial chemoembolization is accepted therapy for hepatocellular carcinoma
(HCC). No randomized trial has demonstrated superiority of chemoembolization compared …

[HTML][HTML] Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed …

AY Helena, CS Sima, J Huang, SB Solomon… - Journal of Thoracic …, 2013 - Elsevier
Background Development of acquired resistance limits the utility of epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKI) for the treatment of EGFR-mutant lung …

[HTML][HTML] Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières …

…, SB Solomon, M Soulen, M Tanaka, T Vogl, B Wood… - European …, 2015 - Springer
Objectives Previous attempts at meta-analysis and systematic review have not provided
clear recommendations for the clinical application of thermal ablation in metastatic colorectal …

Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes—a 10-year experience at a single center

…, MI D'Angelica, WR Jarnagin, SB Solomon… - Radiology, 2016 - pubs.rsna.org
Purpose To identify predictors of oncologic outcomes after percutaneous radiofrequency
ablation (RFA) of colorectal cancer liver metastases (CLMs) and to describe and evaluate a …